ARTICLE | Company News
NewBridge Pharmaceuticals, Eisai sales and marketing update
November 25, 2013 8:00 AM UTC
Eisai and NewBridge partnered to commercialize Eisai's Halaven eribulin in the Middle East. The synthetic analog of halichondrin B is approved to treat locally advanced or metastatic breast cancer th...